Olema Oncology
Oncology Therapeutics · Prescription Drugs
10open roles
200+people
3cities with offices
2007founded
Jobs
≈ $173k – $324k per year (Estimated) · In office · 10+ years exp · Bachelor's Degree · Boston · San Francisco
Machine Learning
Apply
≈ $206k – $386k per year (Estimated) · In office · 10+ years exp · Bachelor's Degree · San Francisco · Boston
Machine Learning
Apply
≈ $99k – $291k per year (Estimated) · In office · Bachelor's Degree · San Francisco · Boston
GMP
Apply
≈ $83k – $245k per year (Estimated) · In office · Bachelor's Degree · Boston
GMP
Apply
≈ $110k – $200k per year (Estimated) · Remote (location not specified) · 3+ years exp · PhD
Apply
≈ $179k – $312k per year (Estimated) · In office · Bachelor's Degree · Boston · San Francisco
Apply
≈ $214k – $372k per year (Estimated) · In office · Bachelor's Degree · San Francisco · Boston
Apply
≈ $86k – $252k per year (Estimated) · In office · 15+ years exp · PhD · Boston · San Francisco
Apply
≈ $102k – $301k per year (Estimated) · In office · 15+ years exp · PhD · San Francisco · Boston
Apply
≈ $190k – $356k per year (Estimated) · In office · 15+ years exp · Bachelor's Degree · San Francisco
GDPR
HIPAA
Management
Service Desk
MedTech
21 CFR Part 11
Apply
Visa sponsorship
0
H-1B filings in 12 months
13
Open roles in United States
In the register as Olema Pharmaceuticals, Inc. t/a Olema Oncology, San Francisco, CA
Other sponsors in the same field
Eli Lilly and Company 420 filings
Regeneron Pharmaceuticals 316 filings
AbbVie 236 filings
Bristol Myers Squibb 218 filings
See 13 open roles Alert me
US Department of Labor · latest filing Apr 15, 2025 · Visa details by country
Growth
Hiring Momentum
34/100
Slowing
Open positions
15
0 opened / 6 closed in 30 days
Median time-to-fill
54 days
faster than 25% of the market
ATS activity
Every ~5 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Early Careers
42% ▲
Biotech
15%
Leadership
12% ▲
HR
12% ▼
Operations
8% ▼
Support
4% ▲
Actively hiring for Early Careers (+3 in 30 days)
Activity Timeline
Added GMP to stack
Oct 2026
Added Veeva to stack
Oct 2026
Added 21 CFR Part 11 to stack
Oct 2026
Added Machine Learning to stack
Oct 2026
Added Windows to stack
Oct 2026
Added Wi-Fi to stack
Oct 2026
Added VPN to stack
Oct 2026
Added Okta to stack
Oct 2026
Added ITIL to stack
Oct 2026
Added DNS to stack
Oct 2026
Added DHCP to stack
Oct 2026
Added Service Desk to stack
Sep 2026
People
Sean Bohen M.D. Ph.D.
Executive Officer, Director
David Myles Ph.D.
Executive Officer
Shane Kovacs
Executive Officer
Naseem Zojwalla M.D.
Executive Officer
Yi Larson
Director
Andrew Rappaport
Director
Cynthia Butitta
Director
Cyrus Harmon Ph.D.
Director
Sandra Horning M.D.
Director
Gorjan Hrustanovic Ph.D.
Director
Graham Walmsley M.D. Ph.D.
Director
Ian Clark
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Tech stack
Technologies named in job postings at Olema Oncology over the last 12 months, by layer, with the share of postings for each.
Technologies in use
13
Postings analysed
17
Stack modernity
62/100
Cloud & platforms
GCP18%
Okta12%
Windows6%
Sign in to see how your skills match this stack
Sign In
Full Olema Oncology tech stack
13 technologies · by team · pay by technology · changes · similar stacks
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Foresite CapitalVia a fund
Wellington ManagementVia a fund
RA Capital ManagementVia a fund
Lightspeed Venture PartnersVia a fund
634 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (
Read more
Report
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (
Read more
Report
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
--Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced a clinical trial collaboration and supply agreement
Read more
Report
Olema Oncology: A Best-In-Class CERAN Platform Anchored By A Pivotal Phase 3 Readout The Market Is Underpricing By 50%+ (NASDAQ:OLMA) Vasuda Healthcare Analytics Seeking Alpha Investing Groups
The Market Dislocation. Olema Oncology is trading at approximately $14.63 per share with a market capitalization of roughly $1.2 billion, representing a...
Read more
Report
Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Poster presentations include new preclinical data demonstrating activity for palazestrant in combination with capivasertib and everolimus, and OP-3136, Olema's KAT6 inhibitor, in combination with palazestrant and other targeted agentsSAN FRANCISCO, Oct. 0
Read more
Report
Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
Data published in Molecular Cancer Therapeutics describes the scientific background underlying the design, discovery and optimization of palazestrant (OP-1250)Pre-clinical results demonstrate that palazestrant, as both a CERAN and a SERD, has a highly dif
Read more
Report
Olema Oncology Provides Clinical Update Reflecting Strong Progress Across OP-1250 Development Program
--Olema Pharmaceuticals, Inc. today announced clinical development progress for OP-1250, a complete estrogen receptor antagonist and a selective ER degrader in development for the treatment of metastatic breast cancer. In the Phase 1 b combination trial w
Read more
Report
Offices
Where the company hires and what each office is for
Cities
3
Hiring now
2
Countries
2
Busiest office
San Francisco
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
San Francisco
United States
HQ
Rogers / Boston
12 open roles 23 posted in 90 days 200-500 est. staff
hires for Early Careers, Leadership, Biotech
Boston
United States
Sales office
Rogers / Boston
10 open roles 19 posted in 90 days 50-200 est. staff
hires for Early Careers, Leadership, Biotech
Dublin
Ireland
Regional office
Dublin / Ireland
1-10 est. staff